Wolverine Asset Management’s Pacira BioSciences PCRX Stock Holding History

Wolverine Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,000	Closed	-$77.6K	–	1858
2025 Q4	$77.6K	Sell	3,000 -8,628	-74%	-$205K	﹤0.01%	1221
2025 Q3	$300K	Hold	11,628	–	–	﹤0.01%	949
2025 Q2	$278K	Hold	11,628	–	–	﹤0.01%	981
2025 Q1	$289K	Buy	+11,628	New	+$278K	﹤0.01%	951
2022 Q2	–	Sell	-10,459	Closed	-$798K	–	2428
2022 Q1	$798K	Buy	+10,459	New	+$697K	0.01%	839

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Wolverine Asset Management's PCRX Position: Q1 2026 in Review

Wolverine Asset Management sold out of Pacira BioSciences (PCRX) in Q1 2026, closing a stake of 3,000 shares — an estimated $77.6K sold.

Wolverine Asset Management first reported a position in PCRX in Q1 2022 and held it in 5 quarters. The position peaked at $798K in Q1 2022. 242 funds tracked by Wall St. Rank hold PCRX as of Q1 2026.

Wolverine Asset Management reported no remaining Pacira BioSciences position as of Q1 2026 after selling out during the quarter.
Wolverine Asset Management sold 3,000 Pacira BioSciences shares in Q1 2026, an estimated $77.6K.
Wolverine Asset Management first reported a position in Pacira BioSciences in Q1 2022 and held it in 5 quarters.
Wolverine Asset Management's Pacira BioSciences position peaked at $798K in Q1 2022.
242 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2026.

Based on Wolverine Asset Management's 13F filing for Q1 2026, filed 4 May 2026.